NeuroNEXT SMA Study

Spinal Muscular Atrophy Biomarker Study

The Spinal Muscular Atrophy Clinic at Nationwide Children’s Hospital and The Ohio State University Wexner Medical Center are part of a select group of 25 national clinical sites that make up the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) program. This effort is one of several groundbreaking spinal muscular atrophy research initiatives taking place at Nationwide Children’s Hospital. Created by the National Institutes of Health, NeuroNEXT fosters cooperation among leading clinical sites, allowing them to efficiently design and implement clinical trials encompassing the entire spectrum of neurologic disease. The goal of this effort is to share and integrate efforts of these clinical trial groups into existing initiatives.

The NeuroNEXT program makes it feasible to rapidly apply new scientific discoveries and to evaluate promising therapies for neurological disorders. This is an excellent opportunity to spur the development of novel treatments, particularly those that might have languished without the benefit of an established trials network and the infrastructure to maintain it. Perhaps it will also enable us to learn more of the lessons that every patient has to teach us.

NeuroNEXT Study Information

For questions and more information on this study or if you wish to participate, please contact Karen Carter, CCRC, Coordinator, Nationwide Children’s Hospital.